sar405838 and Glioblastoma

sar405838 has been researched along with Glioblastoma* in 1 studies

Other Studies

1 other study(ies) available for sar405838 and Glioblastoma

Article	Year
Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Molecular cancer therapeutics, 2018, Volume: 17, Issue:9 Controversy exists surrounding whether heterogeneous disruption of the blood-brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially important when using potent, targeted agents that have a poor penetration across an intact BBB. Efficacy of the murine double minute-2 (MDM2) inhibitor SAR405838 was tested in patient-derived xenograft (PDX) models of GBM. Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Female; Glioblastoma; Humans; Indoles; Male; Mice; Proto-Oncogene Proteins c-mdm2; Spiro Compounds; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2018

Article

Year

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.

Molecular cancer therapeutics, 2018, Volume: 17, Issue:9

Controversy exists surrounding whether heterogeneous disruption of the blood-brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially important when using potent, targeted agents that have a poor penetration across an intact BBB. Efficacy of the murine double minute-2 (MDM2) inhibitor SAR405838 was tested in patient-derived xenograft (PDX) models of GBM.

Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Female; Glioblastoma; Humans; Indoles; Male; Mice; Proto-Oncogene Proteins c-mdm2; Spiro Compounds; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2018